Next report date
Report period
Q1 2024
EPS estimate
0.00EUR
Revenue estimate
63.42 MEUR
−0.0145EUR
−9.76 MEUR
226.91 MEUR
659.49 M
About PHARMING GROUP
Sector
CEO
Sijmen de Vries
Headquarters
Leiden
Website
Founded
1988
ISIN
NL0010391025
FIGI
BBG007Z18601
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0QCO is 0.8905 EUR — it has increased by 1.16% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange PHARMING GROUP NV EUR0.01 stocks are traded under the ticker 0QCO.
PHARMING GROUP NV EUR0.01 is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
0QCO stock is 2.42% volatile and has beta coefficient of 0.74. Check out the list of the most volatile stocks — is PHARMING GROUP NV EUR0.01 there?
0QCO earnings for the last quarter are 0.00 EUR per share, whereas the estimation was −0.01 EUR resulting in a 103.85% surprise. The estimated earnings for the next quarter are 0.00 EUR per share. See more details about PHARMING GROUP NV EUR0.01 earnings.
PHARMING GROUP NV EUR0.01 revenue for the last quarter amounts to 63.10 M EUR despite the estimated figure of 58.34 M EUR. In the next quarter revenue is expected to reach 65.07 M EUR.
Yes, you can track PHARMING GROUP NV EUR0.01 financials in yearly and quarterly reports right on TradingView.
0QCO stock has risen by 1.28% compared to the previous week, the month change is a 12.72% fall, over the last year PHARMING GROUP NV EUR0.01 has showed a 11.51% decrease.
0QCO net income for the last quarter is −2.51 M EUR, while the quarter before that showed 3.18 M EUR of net income which accounts for −178.84% change. Track more PHARMING GROUP NV EUR0.01 financial stats to get the full picture.
Today PHARMING GROUP NV EUR0.01 has the market capitalization of 603.97 M, it has decreased by 6.40% over the last week.
No, 0QCO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0QCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMING GROUP NV EUR0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMING GROUP NV EUR0.01 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMING GROUP NV EUR0.01 stock shows the sell signal. See more of PHARMING GROUP NV EUR0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PHARMING GROUP NV EUR0.01 future price: according to them, 0QCO price has a max estimate of 3.75 EUR and a min estimate of 1.53 EUR. Read a more detailed PHARMING GROUP NV EUR0.01 forecast: see what analysts think of PHARMING GROUP NV EUR0.01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMING GROUP NV EUR0.01 EBITDA is −11.77 M EUR, and current EBITDA margin is −4.49%. See more stats in PHARMING GROUP NV EUR0.01 financial statements.